YOLFTbeta
Climb Bio Inc

Climb Bio Inc

CLYM · NASDAQ · Healthcare / Biotechnology

10.36USD-0.51 (-4.69%)

Price History

Full chart

Market Stats

Previous Close10.87
Open10.76
Day Range10.19 – 10.99
52-Week Range1.54 – 18.33
Volume667.55K
Market Cap669.71M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.82
Dividend Yield0.00%
Beta0.10
50-Day Avg14.22
200-Day Avg9.51

About

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
  • Employees28
  • Headquarters20 William Street, Wellesley Hills, MA, United States, 02481, USA
  • Websitehttps://climbbio.com

Leadership

  • Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMScCEO, President & Director · b. 1976
  • Dr. Susan Altschuller M.B.A., Ph.D.CFO & Principal Accounting Officer · b. 1982
  • Dr. Perrin Wilson B.S., Ph.D.Chief Business Officer · b. 1979
  • Mr. Adam VillaSenior Vice President of Technical Operations
  • Ms. Chandra Adams J.D.Senior VP, General Counsel & Secretary
  • Ms. Ashley JonesSenior Vice President of People & Workforce Strategy
  • Dr. Edgar D. Charles M.D., M.Sc.Chief Medical Officer

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-000000
Cost of Revenue------97.00K
Gross Profit-------97.00K
Operating Expense------67.79M
Operating Income-7.45M-20.93M-35.67M-45.13M-40.27M-82.02M-67.88M
EBITDA-4.70M-11.77M-47.48M-45.24M-35.12M-30.36M-59.75M
Net Income-6.55M-20.67M-47.48M-45.24M-35.12M-73.90M-59.85M
R&D4.02M9.34M23.32M26.21M15.41M14.34M46.62M

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.39M24.63M173.24M134.99M110.47M217.19M167.74M
Total Liabilities783.00K3.06M6.04M6.28M2.87M5.31M7.27M
Total Equity20.61M21.57M167.20M128.72M107.60M211.88M160.47M
Cash21.22M20.49M46.92M43.59M93.11M87.23M35.69M
Total Debt---480.00K349.00K532.00K541.00K
Net Debt-21.22M-20.49M-46.92M-43.10M-92.76M-86.70M-35.14M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.01M-14.10M-36.07M-37.37M-20.60M-15.56M-54.36M
Investing Cash Flow-8.08M-114.97M34.44M68.98M-121.09M2.83M
Financing Cash Flow26.24M4.92M177.23M0841.00K130.73M-21.00K
Capital Expenditure000000186.00K
Free Cash Flow-5.01M-14.10M-36.07M-37.37M-20.60M-15.56M-54.54M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.34%

Earnings

Report DateJul 16, 2021Nov 8, 2021Mar 7, 2022May 16, 2022Aug 15, 2022Nov 14, 2022Mar 6, 2023May 11, 2023Sep 11, 2023Nov 6, 2023Mar 4, 2024May 13, 2024Aug 14, 2024Nov 12, 2024Mar 25, 2025May 14, 2025Aug 14, 2025Nov 6, 2025Mar 9, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-2.37-0.85-0.63-0.50-0.47-0.43-0.33-0.25-0.16-0.14-0.13----0.15-0.15-0.18-0.15-0.19-0.30-0.22-0.19
EPS Actual-0.61-0.701.25-0.50-0.56-0.37-0.29-0.84-0.19-0.15-0.13-0.06-1.81-0.130.04-0.31-0.13-0.19-0.26-0.20-0.18-
Surprise74.26%17.65%298.41%0.00%-19.15%13.95%12.12%-236.00%-21.56%-4.71%-1.08%---126.67%-106.67%27.78%-26.67%-38.89%33.33%18.18%-
Timing-After-hoursAfter-hours-Pre-marketPre-market-After-hours------After-hours-Pre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap669.71M
Enterprise Value537.01M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.00
EPS-0.82
Book Value4.17
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-64.63M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-27.10%
Return on Assets-18.45%
Shares Outstanding57.44M
Shares Float41.29M
Beta0.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 27.57
  • Strong Buy
    2

Ownership Breakdown

Institutions
105.42%
Insiders
0.20%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    11.30M19.68%
  • Adage Capital Partners Gp LLC
    2.51M4.36%
  • Frontier Capital Management CO Inc
    1.94M3.38%
  • T. Rowe Price Associates, Inc.
    1.92M3.34%
  • BRAIDWELL LP
    1.53M2.66%
  • Citadel Advisors Llc
    1.30M2.26%
  • Redmile Group, LLC
    1.23M2.14%
  • Vanguard Capital Management, LLC
    1.18M2.05%
  • Great Point Partners LLC
    1.00M1.74%
  • Affinity Asset Advisors, LLC
    972.00K1.69%
  • Millennium Management LLC
    908.20K1.58%
  • Marshall Wace Asset Management Ltd
    773.12K1.35%

Top Fund Holders

  • T. Rowe Price Health Sciences
    2.01M3.49%
  • Fidelity Small Cap Growth
    1.80M3.13%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.37M2.38%
  • Fidelity Stock Selector Small Cap
    1.19M2.08%
  • Fidelity Advisor Biotechnology I
    996.40K1.73%
  • Fidelity Small Cap Growth K6
    925.12K1.61%
  • iShares Russell 2000 ETF
    900.81K1.57%
  • Fidelity Series Small Cap Opps
    815.70K1.42%